Diseases of the prostate

Reviews in Clinical Gerontology

Volumn 20, Issue 1, 2010, Pages 10-19

  Bright, Elizabeth ^a   Abrams, Paul ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

aged; benign; prostate; prostate cancer

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BICALUTAMIDE; BUSERELIN; CYPROTERONE ACETATE; DOXAZOSIN; DUTASTERIDE; ESTROGEN; FINASTERIDE; FLUTAMIDE; GOSERELIN; LEUPRORELIN; PLACEBO; PLANT EXTRACT; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; TRIPTORELIN;

ANDROGEN THERAPY; BENIGN TUMOR; BLADDER NECK STENOSIS; BLADDER PRESSURE; BLOOD ANALYSIS; BRACHYTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CYSTITIS; DIGITAL RECTAL EXAMINATION; DIZZINESS; ENDOSCOPY; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; GASTROINTESTINAL TRACT EXAMINATION; GLEASON SCORE; GYNECOMASTIA; HEADACHE; HIGH INTENSITY FOCUSED ULTRASOUND; HOLMIUM LASER; HORMONAL THERAPY; HOT FLUSH; HUMAN; IMPOTENCE; INCONTINENCE; INFERTILITY; LAPAROSCOPIC SURGERY; LASER THERMOTHERAPY; LIBIDO DISORDER; LOWER URINARY TRACT SYMPTOM; MALE GENITAL SYSTEM EXAMINATION; MEDICAL HISTORY; METASTASIS; MOOD CHANGE; MUSCLE ATROPHY; NEUROLOGIC EXAMINATION; ORCHIECTOMY; ORTHOSTATIC HYPOTENSION; OSTEOPOROSIS; POSTVOID RESIDUAL URINE VOLUME; PROCTITIS; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE TUMOR; PROSTATECTOMY; RADIOGRAPHY; RETROGRADE EJACULATION; REVIEW; SABAL; SIDE EFFECT; TRANSRECTAL ULTRASONOGRAPHY; TRANSURETHRAL MICROWAVE THERMOTHERAPY; TRANSURETHRAL NEEDLE ABLATION; TRANSURETHRAL RESECTION; UNSPECIFIED SIDE EFFECT; URINALYSIS; URINARY FREQUENCY; URINE FLOW RATE; URINE VOLUME; UROFLOWMETRY; WATCHFUL WAITING; WEAKNESS; WEIGHT GAIN;

EID: 77957355152     PISSN: 09592598     EISSN: 14699036     Source Type: Journal    
DOI: 10.1017/S0959259809990463     Document Type: Review

References (50)

1. Logie J, Clifford GM, Farmer RD. Incidence, prevalence and management of lower urinary tract symptoms in men in the UK. BJU Int 2005; 95: 557-62.
2. Trueman P, Hood SC, Nayak US, Mrazek MF. Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK. BJU Int 1999; 83: 410-15.
3. Abrams P. New words for old: lower urinary tract symptoms for 'prostatism'. BNJ 1994; 308: 929-30.
4. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78.
5. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9.
6. Abrams HP, Feneley RC. The significance of the symptoms associated with bladder outflow obstruction. Urol Int 1978; 33: 171-74.
7. Roehrborn CG, Sech S, Montoya J, Rhodes T, Girman CJ. Interexaminer reliability and validity of a three-dimensional model to assess prostate volume by digital rectal examination. Urology 2001; 57: 1087-92.
8. Yap TL, Cromwell DA, Brown C, Van der Meulen J, Emberton M. The relationship between objective frequency-volume chart data and the I-PSS in men with lower urinary tract symptoms. Eur Urol 2007; 52: 811-8.
9. Abrams P, Chapple C, Khoury S, Roehrborn C, de la Rosette J. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 2009; 181: 1779-87.
10. Reynard JM, Yang Q, Donovan JL et al. The ICS-'BPH' Study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. Br J Urol 1998; 82: 619-23.
11. Chancellor MB, Blaivas JG, Kaplan SA, Axelrod S. Bladder outlet obstruction versus impaired detrusor contractility: the role of outflow. J Urol 1991; 145: 810-12.
12. Abrams PH, Griffiths DJ. The assessment of prostatic obstruction from urodynamic measurements and from residual urine. Br J Urol 1979; 51: 129-34.
13. Barry MJ, Fowler FJ Jr, Bin L, Pitts JC 3rd, Harris CJ, Mulley AG Jr. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol 1997; 157: 10-14; discussion 4-5.
14. Ball AJ, Feneley RC, Abrams PH. The natural history of untreated 'prostatism'. Br J Urol 1981; 53: 613-16.
15. Thomas AW, Cannon A, Bartlett E, Ellis-Jones J, Abrams P. The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic follow-up of untreated bladder outlet obstruction. BJU Int 2005; 96: 1301-6.
16. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 1995; 332: 75-79.
17. Kirby RS, Pool JL. Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future. Br J Urol 1997; 80: 521-32.
18. Lowe F. Alpha-1-adrenoceptor blockade in the treatment of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1999; 2: 110-19.
19. de la Rosette JJ, Kortmann BB, Rossi C, Sonke GS, Floratos DL, Kiemeney LA. Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. J Urol 2002; 167: 1734-39.
20. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41.
21. Andersen JT, Ekman P, Wolf H et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology 1995; 46: 631-37.
22. Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology 1998; 51: 677-86.
23. McConnell JD, Bruskewitz R, Walsh P et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338: 557-63.
24. Kirby RS, Roehrborn C, Boyle P et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61: 119-26.
25. Debruyne FM, Jardin A, Colloi D et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 1998; 34: 169-75.
26. Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998; 280: 1604-9.
27. Bent S, Kane C, Shinohara K et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006; 354: 557-66.
28. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP) - incidence, management, and prevention. Eur Urol 2006; 50: 969-79; discussion 80.
29. Ramon J, Lynch TH, Eardley I et al. Transurethral needle ablation of the prostate for the treatment of benign prostatic hyperplasia: a collaborative multicentre study. Br J Urol 1997; 80: 128-34; discussion 34-5.
30. D'Ancona FC, Francisca EA, Witjes WP, Welling L, Debruyne FM, De La Rosette JJ. Transurethral resection of the prostate vs high-energy thermotherapy of the prostate in patients with benign prostatic hyperplasia: long-term results. Br J Urol 1998; 81: 259-64.
31. Hoffman RM, MacDonald R, Monga M, Wilt TJ. Transurethral microwave thermotherapy vs transurethral resection for treating benign prostatic hyperplasia: a systematic review. BJU Int 2004; 94: 1031-6.
32. Madersbacher S, Schatzl G, Djavan B, Stulnig T, Marberger M. Long-term outcome of transrectal high-intensity focused ultrasound therapy for benign prostatic hyperplasia. Eur Urol 2000; 37: 687-94.
33. Schatzl G, Madersbacher S, Djavan B, Lang T, Marberger M. Two-year results of transurethral resection of the prostate versus four 'less invasive' treatment options. Eur Urol 2000; 37: 695-701.
34. Ruszat R, Wyler S, Forster T et al. Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol 2007; 51: 1031-8; discussion 8-41.
35. Horasanli K, Silay MS, Altay B, Tanriverdi O, Sarica K, Miroglu C. Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70 ml: a short-term prospective randomized trial. Urology 2008; 71: 247-51.
36. Bouchier-Hayes DM, Anderson P, Van Appledorn S, Bugeja P, Costello AJ. KTP laser versus transurethral resection: early results of a randomized trial. J Endourol 2006; 20: 580-85.
37. Alivizatos G, Skolarikos A, Chalikopoulos D et al. Transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas >80 ml: 12-month results of a randomized prospective study. Eur Urol 2008; 54: 427-37.
38. Naspro R, Bachmann A, Gilling P et al. A review of the recent evidence (2006-2008) for 532-nm photoselective laser vaporisation and holmium laser enucleation of the prostate. Eur Urol 2009; 55: 1345-57.
39. Ahyai SA, Lehrich K, Kuntz RM. Holmium laser enucleation versus transurethral resection of the prostate: 3-year follow-up results of a randomized clinical trial. Eur Urol 2007; 52: 1456-63.
40. Wilson LC, Gilling PJ, Williams A et al. A randomised trial comparing holmium laser enucleation versus transurethral resection in the treatment of prostates larger than 40 grams: results at 2 years. Eur Urol 2006; 50: 569-73.
41. Gupta N, Sivaramakrishna, Kumar R, Dogra PN, Seth A. Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40 g. BJU Int 2006; 97: 85-89.
42. George NJ. Natural history of localised prostatic cancer managed by conservative therapy alone. Lancet 1988; 1: 494-97.
43. Chodak GW, Thisted RA, Gerber GS et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242-8.
44. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 2095-101.
45. Weldon VE, Tavel FR, Neuwirth H. Continence, potency and morbidity after radical perineal prostatectomy. J Urol 1997; 158: 1470-75.
46. Stolzenburg JU, Rabenalt R, Do M et al. Endoscopic extraperitoneal radical prostatectomy: oncological and functional results after 700 procedures. J Urol 2005; 174: 1271-75; discussion 5.
47. Dahl DM, Barry MJ, McGovern FJ, Chang Y, Walker-Corkery E, McDougal WS. A prospective study of symptom distress and return to baseline function after open versus laparoscopic radical prostatectomy. J Urol 2009; 182: 956-65.
48. Eckman MH, Ying J, Hertzfeld K, Kumar N, Barrett W. Longitudinal analysis of genitourinary and bowel symptoms in prostate cancer patients following brachytherapy. Am J Clin Oncol 2009 (Epub ahead of print, 24 July).
49. Colberg JW, Decker RH, Khan AM, McKeon A, Wilson LD, Peschel RE. Surgery versus implant for early prostate cancer: results from a single institution, 1992-2005. Cancer J 2007; 13: 229-32.
50. Polascik TJ, Pound CR, DeWeese TL, Walsh PC. Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis. Urology 1998; 51: 884-89; discussion 9-90.